These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 18799925)

  • 1. Pulmonary toxicity associated with vinorelbine-based chemotherapy in breast cancer.
    Yanagitani N; Shimizu Y; Kaira K; Tatsuno S; Sunaga N; Ishizuka T; Mori M
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1619-21. PubMed ID: 18799925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
    Lin NU; Seah DS; Gelman R; Desantis S; Mayer EL; Isakoff S; Dipiro P; Krop IE; Come SE; Weckstein D; Winer EP; Burstein HJ
    Breast Cancer Res Treat; 2013 Jun; 139(2):403-10. PubMed ID: 23645007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
    De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
    BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab.
    Munzone E; Nolè F; Sanna G; Goldhirsch A
    Breast; 2005 Oct; 14(5):380-3. PubMed ID: 16216740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
    Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
    Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversible posterior leukoencephalopathy syndrome induced by vinorelbine.
    Chen YH; Huang CH
    Clin Breast Cancer; 2012 Jun; 12(3):222-5. PubMed ID: 22424944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vinorelbine (Navelbine) in the treatment of breast cancer: the European experience.
    Fumoleau P; Delozier T; Extra JM; Canobbio L; Delgado FM; Hurteloup P
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):22-8; discussion 28-9. PubMed ID: 7740332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
    Chan A; Martin M; Untch M; Gil MG; Guillem-Porta V; Wojtukiewicz M; Kellokumpu-Lehtinen P; Sommer HL; Georgoulias V; Battelli N; Pawlicki M; Aubert D; Bourlard T; Gasmi J; Villanova G; Petruzelka L;
    Br J Cancer; 2006 Oct; 95(7):788-93. PubMed ID: 16969343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
    N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
    Tokudome N; Ito Y; Hatake K; Toi M; Sano M; Iwata H; Sato Y; Saeki T; Aogi K; Takashima S
    Anticancer Drugs; 2008 Aug; 19(7):753-9. PubMed ID: 18594220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vinorelbine as palliative therapy in advanced breast cancer.
    Gasco M; Gardin G; Repetto L; Campora E; Rosso R
    Anticancer Res; 1997; 17(2B):1431-3. PubMed ID: 9137510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study.
    Vokes EE; Haraf DJ; Masters GA; Hoffman PC; Drinkard LC; Ferguson M; Olak J; Watson S; Golomb HM
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):48-52. PubMed ID: 8610237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients.
    Pronzato P; Landucci M; Vaira F; Vigani A; Bertelli G
    Anticancer Res; 1994; 14(3B):1413-5. PubMed ID: 8067715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions for vinorelbine (Navelbine).
    Hortobagyi GN
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):80-6; discussion 86-7. PubMed ID: 7740338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer.
    Bayo-Calero JL; Mayordomo JI; Sánchez-Rovira P; Pérez-Carrión R; Illaramendi JJ; García-Bueno JM; González-Flores E; Crespo C; Ramos-Vázquez M; García-Palomo A; Ruiz-Borrego M; de la Haba J; Gómez-Bernal A; Yubero-Esteban A
    Clin Breast Cancer; 2008 Jun; 8(3):264-8. PubMed ID: 18650157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.